Matches in SemOpenAlex for { <https://semopenalex.org/work/W2074684694> ?p ?o ?g. }
- W2074684694 endingPage "259" @default.
- W2074684694 startingPage "251" @default.
- W2074684694 abstract "1. Octimibate, 8-[(1,4,5-triphenyl-1H-imidazol-2-yl)oxy]octanoic acid, is reported to have antithrombotic properties. This is in addition to its antihyperlipidaemic effects which are due to inhibition of acylCoA:cholesterol acyltransferase (ACAT). The aim of this study was to investigate the mechanism of the antithrombotic effect of octimibate, and to determine whether the effects of octimibate are mediated through prostacyclin receptors. 2. In suspensions of washed (plasma-free) human platelets, octimibate is a potent inhibitor of aggregation; its IC50 is approx. 10 nM for inhibition of aggregation stimulated by several different agonists, including U46619 and ADP. The inhibitory effects of octimibate on aggregation are not competitive with the stimulatory agonist; the maximal response is suppressed but there is no obvious shift in potency of the agonist. In platelet-rich plasma, octimibate inhibits agonist-stimulated aggregation with an IC50 of approx. 200 nM. 3. Octimibate also inhibits agonist-stimulated rises in the cytosolic free calcium concentration, [Ca2+]i, in platelets. Both Ca2+ influx and release from intracellular stores are inhibited. The effects of octimibate on aggregation and [Ca2+]i are typical of agents that act via elevation of adenosine 3':5'-cyclic monophosphate (cyclic AMP). Similar effects are seen with forskolin, prostacyclin (PGl2) and iloprost (a stable PGl2 mimetic). 4. Octimibate increases cyclic AMP concentrations in platelets and increases the cyclic AMP-dependent protein kinase activity ratio. Octimibate stimulates adenylyl cyclase activity in human platelet membranes, with an EC50 of 200 nM. The maximal achievable activation of adenylyl cyclase by octimibate is 60% of that obtainable with iloprost. Octimibate has no effect on the cyclic GMP-inhibited phosphodiesterase (phosphodiesterase-ITI), which is the major cyclic AMP-degrading enzyme in human platelets.5. Octimibate inhibits, apparently competitively, the binding of [3H]-iloprost (a stable PGl2 mimetic) to platelet membranes; the estimated Ki is 150 nm. 6. The platelets of different species show considerable differences in the apparent potency of their inhibition of aggregation by octimibate; platelets from cynomolgus monkeys are 3 fold more sensitive than those from humans, while rat, cat and cow platelets are 50, 100, and 250 fold less sensitive than human platelets. The sensitivity of these different species to iloprost, however, varies over a range of only 10 fold with no obvious difference between primates and non-primates. 7. Octimibate appears to be a potent agonist (aggregation), or partial agonist (adenylyl cyclase), at prostacyclin receptors and is the first non-prostanoid agent of this type to be identified. The species differences in relative potency of octimibate and iloprost may reflect the existence of receptor subtypes." @default.
- W2074684694 created "2016-06-24" @default.
- W2074684694 creator A5022214520 @default.
- W2074684694 creator A5023432977 @default.
- W2074684694 creator A5025306204 @default.
- W2074684694 creator A5034566838 @default.
- W2074684694 creator A5035296398 @default.
- W2074684694 creator A5038557255 @default.
- W2074684694 creator A5041077738 @default.
- W2074684694 creator A5045297396 @default.
- W2074684694 creator A5053765063 @default.
- W2074684694 creator A5068945189 @default.
- W2074684694 creator A5069287119 @default.
- W2074684694 creator A5069822390 @default.
- W2074684694 creator A5072789325 @default.
- W2074684694 creator A5073536299 @default.
- W2074684694 creator A5084382070 @default.
- W2074684694 creator A5088815397 @default.
- W2074684694 date "1991-01-01" @default.
- W2074684694 modified "2023-09-27" @default.
- W2074684694 title "Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor" @default.
- W2074684694 cites W108110864 @default.
- W2074684694 cites W1277224710 @default.
- W2074684694 cites W183678651 @default.
- W2074684694 cites W1936333617 @default.
- W2074684694 cites W1972506518 @default.
- W2074684694 cites W1986730217 @default.
- W2074684694 cites W1987268939 @default.
- W2074684694 cites W1994794688 @default.
- W2074684694 cites W1997672871 @default.
- W2074684694 cites W2001334960 @default.
- W2074684694 cites W2014771565 @default.
- W2074684694 cites W2021403302 @default.
- W2074684694 cites W2021624237 @default.
- W2074684694 cites W2024003911 @default.
- W2074684694 cites W2024065582 @default.
- W2074684694 cites W2029744477 @default.
- W2074684694 cites W2044723736 @default.
- W2074684694 cites W2057591548 @default.
- W2074684694 cites W2064800522 @default.
- W2074684694 cites W2065993385 @default.
- W2074684694 cites W2073824580 @default.
- W2074684694 cites W2074631079 @default.
- W2074684694 cites W2075029427 @default.
- W2074684694 cites W2075156914 @default.
- W2074684694 cites W2113943014 @default.
- W2074684694 cites W2128635872 @default.
- W2074684694 cites W213009695 @default.
- W2074684694 cites W2149580070 @default.
- W2074684694 cites W2169503005 @default.
- W2074684694 cites W2196351397 @default.
- W2074684694 cites W2226662642 @default.
- W2074684694 cites W2264789091 @default.
- W2074684694 cites W2304916517 @default.
- W2074684694 cites W2400057147 @default.
- W2074684694 cites W2414416705 @default.
- W2074684694 cites W4251572576 @default.
- W2074684694 cites W4293247451 @default.
- W2074684694 cites W960177770 @default.
- W2074684694 doi "https://doi.org/10.1111/j.1476-5381.1991.tb12162.x" @default.
- W2074684694 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1917884" @default.
- W2074684694 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1710526" @default.
- W2074684694 hasPublicationYear "1991" @default.
- W2074684694 type Work @default.
- W2074684694 sameAs 2074684694 @default.
- W2074684694 citedByCount "44" @default.
- W2074684694 countsByYear W20746846942013 @default.
- W2074684694 countsByYear W20746846942016 @default.
- W2074684694 countsByYear W20746846942017 @default.
- W2074684694 countsByYear W20746846942021 @default.
- W2074684694 crossrefType "journal-article" @default.
- W2074684694 hasAuthorship W2074684694A5022214520 @default.
- W2074684694 hasAuthorship W2074684694A5023432977 @default.
- W2074684694 hasAuthorship W2074684694A5025306204 @default.
- W2074684694 hasAuthorship W2074684694A5034566838 @default.
- W2074684694 hasAuthorship W2074684694A5035296398 @default.
- W2074684694 hasAuthorship W2074684694A5038557255 @default.
- W2074684694 hasAuthorship W2074684694A5041077738 @default.
- W2074684694 hasAuthorship W2074684694A5045297396 @default.
- W2074684694 hasAuthorship W2074684694A5053765063 @default.
- W2074684694 hasAuthorship W2074684694A5068945189 @default.
- W2074684694 hasAuthorship W2074684694A5069287119 @default.
- W2074684694 hasAuthorship W2074684694A5069822390 @default.
- W2074684694 hasAuthorship W2074684694A5072789325 @default.
- W2074684694 hasAuthorship W2074684694A5073536299 @default.
- W2074684694 hasAuthorship W2074684694A5084382070 @default.
- W2074684694 hasAuthorship W2074684694A5088815397 @default.
- W2074684694 hasBestOaLocation W20746846942 @default.
- W2074684694 hasConcept C126322002 @default.
- W2074684694 hasConcept C134018914 @default.
- W2074684694 hasConcept C170493617 @default.
- W2074684694 hasConcept C185592680 @default.
- W2074684694 hasConcept C2776991684 @default.
- W2074684694 hasConcept C2778938600 @default.
- W2074684694 hasConcept C2779178603 @default.
- W2074684694 hasConcept C2779276759 @default.
- W2074684694 hasConcept C2781128415 @default.
- W2074684694 hasConcept C55493867 @default.